Capital Analysts LLC’s ProQR Therapeutics PRQR Stock Holding History

Capital Analysts LLC’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-500	Closed	-$2K	–	795
2020 Q3	$2K	Hold	500	–	–	﹤0.01%	712
2020 Q2	$3K	Buy	+500	New	+$2.7K	﹤0.01%	647

Other funds holding PRQR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Capital Analysts LLC's PRQR Position: Q4 2020 in Review

Capital Analysts LLC sold out of ProQR Therapeutics (PRQR) in Q4 2020, closing a stake of 500 shares — an estimated $2K sold.

Capital Analysts LLC first reported a position in PRQR in Q2 2020 and held it in 2 quarters. The position peaked at $3K in Q2 2020. 46 funds tracked by Wall St. Rank hold PRQR as of Q4 2020.

Capital Analysts LLC reported no remaining ProQR Therapeutics position as of Q4 2020 after selling out during the quarter.
Capital Analysts LLC sold 500 ProQR Therapeutics shares in Q4 2020, an estimated $2K.
Capital Analysts LLC first reported a position in ProQR Therapeutics in Q2 2020 and held it in 2 quarters.
Capital Analysts LLC's ProQR Therapeutics position peaked at $3K in Q2 2020.
46 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2020.

Based on Capital Analysts LLC's 13F filing for Q4 2020, filed 16 Feb 2021.